Ally Bridge Group, Cambridge Innovation Capital, Chimera Partners, GE Healthcare, LGT Impact Ventures, Lightrock, PFM Health Sciences, RPMI Railpen, SoftBank Vision Fund II, Tencent Holdings and Watrium’s $600m venture financing deal with CMR Surgical was the medical devices industry’s biggest artificial intelligence deal of Q2 2021 as artificial intelligence deals worth $2.1bn were announced globally in the quarter, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked a decrease of 43.6% over the previous quarter and a drop of 64.3% when compared with the last four-quarter average of $5.8bn.
In terms of number of artificial intelligence deals, the sector saw a drop of 28.63% with 43 deals in Q2 2021 against the average of 60.25 deals in the last four-quarters.
In value terms, North America led the activity with artificial intelligence deals worth $1.17bn.
medical devices industry artificial intelligence deals in Q2 2021: Top deals
The top five medical devices industry artificial intelligence deals accounted for 60.9% of the overall value during Q2 2021.
The combined value of the top five artificial intelligence deals stood at $1.26bn, against the overall value of $2.1bn recorded for the quarter.
The top five medical devices industry artificial intelligence deals of Q2 2021 tracked by GlobalData were:
1) Ally Bridge Group, Cambridge Innovation Capital, Chimera Partners, GE Healthcare, LGT Impact Ventures, Lightrock, PFM Health Sciences, RPMI Railpen, SoftBank Vision Fund II, Tencent Holdings and Watrium’s $600m venture financing deals with CMR Surgical
2) The $255m venture financing with InSilico Medicine by B Capital Group Management, Baidu Ventures, Bold Capital Partners, CITIC Industrial Investment Fund Management, Deerfield ManagementLP, Eight Roads Ventures, Formic Ventures, Lake Bleu Capital, Lilly Asia ventures, Maison Capital Group, Mirae Asset Capital, Orbimed Advisors, Pavilion Capital Partners, President International Development, Qiming Venture Partners, Sage Partners, Sequoia Capital China, Sinovation Ventures and Warburg Pincus
3) 8VC , Adage Capital Partners, Biospring Partners, Bristol-Myers Squibb, D1 Capital Partners, General Atlantic, General Catalyst Partners, Kaiser Permanente Ventures, KdT Ventures, LabCorp Venture Fund, Merck Global Health Innovation Fund, Polaris Partners, Refactor Capital and Tiger Global Management’s $165m venture financing of PathAI
4) The $130m venture financing of Huma Therapeutics by HAT SGR, Hitachi Ventures, Leaps by Bayer, Samsung NEXT Fund, Sony Innovation Fund and Unilever Ventures
5) AME Cloud Ventures, Ardea Partners, Aspect Ventures, AXA Venture Partners, Canvas Ventures, Centene, General Atlantic, NGP Capital and Workday Ventures’ venture financing with Vida Health for $110m.
